B-hSIRPα/hCD47 Mice

Basic Information

Strain Name
C57BL/6-SIRPα tm1(SIRPα) Cd47 tm1(CD47) /Bcgen
Stock Number
120525
Common Name
B-hSIRPα/hCD47 mice
Source/Investigator
Bcgen (Beijing Biocytogen Co., Ltd)
Related Genes
CD47 (CD47 molecule); SIRPα(Signal regulatory protein alpha)
Species
C57BL/6
Appearance
Black
Genotypes
Homozygous

Targeting Strategy

Details

Phenotype

Protein Expression Analysis

 

 

Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hSIRPα /hCD47 mice were analyzed by flow cytometry. Mouse CD47+ T cells were detectable in the C57BL/6 mice, mouse SIRPα + T cells were detectable in both WT C57BL/6 mice and homozygous B-hSIRPα / hCD47 mice, while human CD47+ and SIRPα + T cells were detectable in the homozygous B-hSIRPA/hCD47 mice. This might result from the cross-recognition of hSIRPα by anti-mSIRPα antibodies

Application

Human CD47 mAb Efficacy and Toxicity Evaluation (MC38-hCD47 Cell Line)

B-hSIRPA-hCD47-Mice -application-MC38-hCD47

 

 

 

 

 

 

 

Colon cancer MC38-hCD47 cells were subcutaniously implanted into the
homozygous hSIRPα /hCD47 mice. The mice were divided into control and
treatment groups as the tumor volume was 150±50 mm3 (n=5). The result
indicated that B-hSIRPα /hCD47 mice model was an effective tool for in vivo hCD47 antibody efficacy study. The average ±SEM of tumor sizes are shown in the figure.

Human CD47 mAb Toxicity Evaluation


B-hSIRPA-hCD47-Mice-Human-CD47-mAb-toxicity-evaluation-table

 

 

 

 

 

Anti-hCD47 antibodies were i.p. injected into homozygous hSIRPα/hCD47 mice. Blood were collected two days after the treatment and analyzed by Blood Routine Test.

B-hSIRPA-hCD47-anti-hCD47

Anti-hCD47 antibodies were i.p. injected into homozygous hSIRPα/hCD47 mice.Blood were collected two days after the treatment and analyzed by Blood Biochemical Test.

B-hSIRPA-hCD47-anti-hCD47-antibodies-homozygous

 

 

 

 

 

 

 

 

 

Anti-hCD47 antibodies were i.p. injected into homozygous hSIRPα /hCD47 mice. Blood were collected at the study end point and analyzed by Blood Routine Test.

B-hSIRPA-hCD47-anti-hCD47-blood-were-collected

 

 

 

 

Blood were collected at the endpoint of the treatment and analyzed by Blood Biochemical Test.

Human SIRPα mAb Efficacy Evaluation (MC38-hCD47 Cell Line)

B-hSIRPA-hCD47-human-SIRPA-mAb

 

 

 

 

 

 

 

Murine colon cancer MC38-hCD47 cells were subcutaneously implanted into homozygous B-hSIRPα/hCD47 mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=6). Three human SIRPα antibodies differently inhibited tumor growth, confirming that the B-hSIRPα/hCD47 mouse model is a powerful tool for in vivo SIRPα antibody pharmacological efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

References

  1. PNAS July 2, 2013 110 (27) 11103-11108; doi: 10.1073/pnas.1305569110
  2. Curr Opin Immunol. 2012 April ; 24(2): 225–232. doi:10.1016/j.coi.2012.01.010
  3.  Genes to Cells (2015) 20, 451–463 doi:10.1111/gtc.12238
Back to top